Ambu A/S Q4 2026 Earnings Results & Report

Ambu A/S EPS Results

• Actual EPS: $0.14
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Ambu A/S Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Ambu A/S (OTCMKTS:AMBBY) is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. Its products are designed to support clinical procedures while reducing the need for cleaning, disinfection and reprocessing associated with reusable equipment.

The company’s portfolio includes single-use endoscopy systems, such as the aScope range of flexible endoscopes and related visualization equipment, as well as products for anesthesia, airway management, ventilation, resuscitation and patient monitoring. Ambu also supplies diagnostic and monitoring accessories, including electrodes and other disposable devices used in clinical care.

Founded in Denmark in 1937, Ambu has a history of developing equipment for emergency care and anesthesia, including the self-inflating resuscitation bag commonly known as the Ambu bag. The company serves healthcare markets internationally through direct operations and distribution networks across Europe, North America, Asia-Pacific and other regions. Ambu is headquartered in Ballerup, Denmark, and is led by Chief Executive Officer Britt Meelby Jensen.